Genmab A/S ADR (GMAB) Stock Price, Quote & News

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 20 27 28

Website: www.genmab.com

Address:

Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark

SenefAS Apr. 21 at 8:16 PM

$GMAB Genmab a lot of options tonight… Something is cooking 🤔 $NVO $JNJ

1 · Reply

OptionRunners Apr. 21 at 2:34 PM

$GMAB

0 · Reply

stockwatcherking Apr. 21 at 2:26 PM

$GMAB Aggressive $30 call flow here in the August strikes.

0 · Reply

Night_Owl_Biotech Apr. 19 at 9:28 PM

Analysts project $JAZZ to generate roughly the same total revenue dollars as $HZNP mgmt/BOD projected for the 5 years after Amgen paid $28.2B to acquire them. Does this suggest JAZZ would be worth about the same if JAZZ were ever acquired? JAZZ generated 92% gross margins in FY25. HZNP projected 85% gross margins over the 5-year period. Does the higher gross margin profile suggest JAZZ would merit a higher multiple than HZNP (all other things being equal). This is not investment advice. All the same, we've wondered how long JAZZ investors will wait before demanding a valuation consistent with their underlying business. Incidentally, $GMAB 5-year analyst consensus are also very close to HZNP (in fact slightly higher 10-year) but we're giving a quarter to 2 to digest their recent acquisition. More on GMAB soon. $XBI $IBB

0 · Reply

Pika_Capital Apr. 14 at 1:28 PM

$GMAB cash pile keeps growing. This should be trading at 40 bucks minimum

0 · Reply

SenefAS Apr. 14 at 11:46 AM

$JNJ $GMAB Boommm $4B sales for Darzalex Q1 Genmab & Johnson… Tic tac 🙃

0 · Reply

DonCorleone77 Apr. 14 at 10:54 AM

$GMAB Genmab reports Darzalex Q1 worldwide sales $3.964B Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S., as reported by J&J (JNJ), were $3.964B in the Q1. Net trade sales were $2.208M in the U.S. and $1.756M in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.

0 · Reply

SenefAS Apr. 9 at 7:22 AM

$GMAB Genmab is still undervalued a this level… $NVO $JNJ $PFE

0 · Reply

Night_Owl_Biotech Apr. 5 at 2:36 PM

Revenue multiples & other valuation data for all commercial-stage bios forecast to generate $800MM or more in FY26 revenues (sorted highest enterprise value to lowest). This is not investment advice. Our observations for entertainment purposes only; $NBIX sells 2 FDA approved therapies & trades at lower multiples of analyst consensus than peers (notice the 98% gross margin too). $GMAB is off 20%+ from recent highs but now appears to trade at reasonable multiples v peers. Of course if analyst consensus are not credible then all bets are off. $OGN is leveraged to the hilts like some piss poor south American country. Low gross margins do not help but leverage works both ways. $SRPT & $LEGN have had rough goes of it but its been months now. Though there's very new updates on Sarepta but if all other things have settled down then?

1 · Reply

Quantumup Apr. 2 at 3:41 PM

Mizuho⬆️ $CRBP's PT to $40 and reiterated at an Outperform rating. MRUS - $GMAB JNJ - $NBTX MRK $BCAX Mizuho said—In light of previously reported 4Q results and our recent conversations w/ mgmt, we increase our PT to $40 (vs. $39 prior) on updated assumptions for CRB-701 ('701) and CRB-913 ('913). From CRBP's 4Q update, notably, (1) CBRP remains on track for three data updates in 2026, and (2) incremental (but of very little significance) was deprioritization of CRB-601 (an asset that we nor investors paid particular attention to). Our model includes major changes primarily around our assumptions for '701, where we now include the head and neck squamous cell carcinoma/HNSCC opportunity, while removing some previously modeled '701 opportunities (we provide further details within). Net net, we maintain our overall bullish view and, with the shares trading at near cash/share levels, seeing favorable risk/reward ahead of multiple upcoming data catalysts, we reiterate our OP rating on CRBP.

0 · Reply